These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37658631)

  • 21. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
    Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
    Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology.
    Hancox JC; Mitcheson JS
    Br J Pharmacol; 2006 Nov; 149(5):457-9. PubMed ID: 16967047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.
    Deacon M; Singleton D; Szalkai N; Pasieczny R; Peacock C; Price D; Boyd J; Boyd H; Steidl-Nichols JV; Williams C
    J Pharmacol Toxicol Methods; 2007; 55(3):238-47. PubMed ID: 17141530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BeKm-1, a peptide inhibitor of human ether-a-go-go-related gene potassium currents, prolongs QTc intervals in isolated rabbit heart.
    Qu Y; Fang M; Gao B; Chui RW; Vargas HM
    J Pharmacol Exp Ther; 2011 Apr; 337(1):2-8. PubMed ID: 21205913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of the risk of QT prolongation among SSRIs.
    Funk KA; Bostwick JR
    Ann Pharmacother; 2013 Oct; 47(10):1330-41. PubMed ID: 24259697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells.
    Jehle J; Ficker E; Wan X; Deschenes I; Kisselbach J; Wiedmann F; Staudacher I; Schmidt C; Schweizer PA; Becker R; Katus HA; Thomas D
    Br J Pharmacol; 2013 Mar; 168(5):1215-29. PubMed ID: 23061993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastrointestinal absorption of pimozide is enhanced by inhibition of P-glycoprotein.
    Morishita H; Okawa K; Ishii M; Mizoi K; Ito MA; Arakawa H; Yano K; Ogihara T
    PLoS One; 2020; 15(10):e0232438. PubMed ID: 33119612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk.
    Pollard CE; Abi Gerges N; Bridgland-Taylor MH; Easter A; Hammond TG; Valentin JP
    Br J Pharmacol; 2010 Jan; 159(1):12-21. PubMed ID: 20141516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A history of the role of the hERG channel in cardiac risk assessment.
    Rampe D; Brown AM
    J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. QT interval prolongation and cardiac risk assessment for novel drugs.
    Picard S; Lacroix P
    Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Probable quetiapine-mediated prolongation of the QT interval.
    Aghaienia N; Brahm NC; Lussier KM; Washington NB
    J Pharm Pract; 2011 Oct; 24(5):506-12. PubMed ID: 21844216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular predictors of drug-induced prolongation of the QT interval.
    Dilaveris PE
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):105-18. PubMed ID: 15853698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concomitant use of antipsychotics and drugs that may prolong the QT interval.
    Roe CM; Odell KW; Henderson RR
    J Clin Psychopharmacol; 2003 Apr; 23(2):197-200. PubMed ID: 12640222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Other drugs acting on nervous system associated with QT-interval prolongation.
    Keller GA; Ponte ML; Di Girolamo G
    Curr Drug Saf; 2010 Jan; 5(1):105-11. PubMed ID: 20210727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of hERG channel trafficking: an under-explored mechanism for drug-induced QT prolongation.
    Yeung KS; Meanwell NA
    ChemMedChem; 2008 Oct; 3(10):1501-2. PubMed ID: 18696522
    [No Abstract]   [Full Text] [Related]  

  • 36. Reversible dimers of the atypical antipsychotic quetiapine inhibit p-glycoprotein-mediated efflux in vitro with increased binding affinity and in situ at the blood-brain barrier.
    Emmert D; Campos CR; Ward D; Lu P; Namanja HA; Bohn K; Miller DS; Sharom FJ; Chmielewski J; Hrycyna CA
    ACS Chem Neurosci; 2014 Apr; 5(4):305-17. PubMed ID: 24483607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.
    Witchel HJ; Hancox JC
    Clin Exp Pharmacol Physiol; 2000 Oct; 27(10):753-66. PubMed ID: 11022966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.
    De Ponti F; Poluzzi E; Cavalli A; Recanatini M; Montanaro N
    Drug Saf; 2002; 25(4):263-86. PubMed ID: 11994029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
    Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
    Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Electropharmacological assessment of the risk of drug-induced long-QT syndrome using native cardiac cells and cultured cells expressing HERG channels].
    Nakaya H
    Nihon Yakurigaku Zasshi; 2003 Jun; 121(6):384-92. PubMed ID: 12835532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.